3 Matching Annotations
  1. Last 7 days
    1. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience

      [Paper-level Aggregated] PMCID: PMC3260002

      Evidence Type(s): Oncogenic, Predictive, Prognostic

      Justification: Oncogenic: The presence of DNMT3A exon 23 mutations, particularly at the R882 codon, is associated with acute myeloid leukemia (AML), indicating a role in tumorigenesis. Predictive: The identification of specific mutations in DNMT3A may help predict the response to certain treatments in AML patients, as these mutations are known to influence disease characteristics. Prognostic: The detection of DNMT3A mutations, especially at the R882 codon, can provide information about the likely course and outcome of the disease in AML patients.

      Gene→Variant (gene-first): DNMT3A(1788):R882 DNMT3A(1788):R882C DNMT3A(1788):R882H DNMT3A(1788):R882P DNMT3A(1788):W893 DNMT3A(1788):W893S

      Genes: DNMT3A(1788)

      Variants: R882 R882C R882H R882P W893 W893S

    2. DNMT3A exon 23 screening was performed on available samples coming from 288 AML patients aged from 18 to 65-year old and treated in Toulouse between 2000 and 2009. DNMT3A exon 23 mutations were detected in 39 patients (1

      [Paragraph-level] PMCID: PMC3260002 Section: RESULTS PassageIndex: 3

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the detection of DNMT3A exon 23 mutations in AML patients, indicating that these mutations are associated with the disease, which supports their use in defining or confirming the disease. Oncogenic: The mention of DNMT3A mutations in AML patients suggests that these somatic variants contribute to tumor development or progression, as they are identified in a cancer context.

      Gene→Variant (gene-first): 1788:R882 1788:R882C 1788:R882H 1788:R882P 1788:W893 1788:W893S

      Genes: 1788

      Variants: R882 R882C R882H R882P W893 W893S

    3. DNMT3A exon 23 screening was performed on available samples coming from 288 AML patients aged from 18 to 65-year old and treated in Toulouse between 2000 and 2009. DNMT3A exon 23 mutations were detected in 39 patients (1

      [Paragraph-level] PMCID: PMC3260002 Section: RESULTS PassageIndex: 3

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the detection of DNMT3A exon 23 mutations in AML patients, indicating that these mutations are associated with the disease, which supports their use in defining or confirming the disease. Oncogenic: The mention of DNMT3A mutations in AML patients suggests that these somatic variants contribute to tumor development or progression, as they are identified in a cancer context.

      Gene→Variant (gene-first): 1788:R882 1788:R882C 1788:R882H 1788:R882P 1788:W893 1788:W893S

      Genes: 1788

      Variants: R882 R882C R882H R882P W893 W893S